47.77
+0.45(+0.95%)
Currency In USD
| Previous Close | 47.32 |
| Open | 46.55 |
| Day High | 47.93 |
| Day Low | 46.46 |
| 52-Week High | 72.29 |
| 52-Week Low | 27.05 |
| Volume | 110,656 |
| Average Volume | 452,612 |
| Market Cap | 2.8B |
| PE | -19.66 |
| EPS | -2.43 |
| Moving Average 50 Days | 50.48 |
| Moving Average 200 Days | 50.39 |
| Change | 0.45 |
If you invested $1000 in Apogee Therapeutics, Inc. (APGE) since IPO date, it would be worth $2,250.12 as of December 26, 2024 at a share price of $47.77. Whereas If you bought $1000 worth of Apogee Therapeutics, Inc. (APGE) shares 6 months ago, it would be worth $1,248.89 as of December 26, 2024 at a share price of $47.77.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG333, its Novel Half-Life Extended TSLP Antibody for the Treatment of Respiratory and Broader I&I Conditions
GlobeNewswire Inc.
Dec 10, 2024 12:00 PM GMT
Interim safety and pharmacokinetic data from Phase 1 healthy volunteers trial anticipated in 2H 2025 APG777 + APG333 can potentially address key drivers of respiratory diseases more broadly versus monotherapy Preclinical proof-of-concept achieved f
Apogee Therapeutics Highlights Progress and Best-in-Class Potential of Novel Biologic Programs for I&I Diseases at 2024 Inaugural R&D Day
GlobeNewswire Inc.
Dec 02, 2024 11:00 AM GMT
Positive interim Phase 1 data indicate APG808 was well-tolerated with half-life of approximately 55 days, supporting potential for 2- to 3- month dosing and demonstrating deep and sustained inhibition of biomarkers Data up to 12 months reinforce APG7
Apogee Therapeutics Announces Agenda for Virtual R&D Day
GlobeNewswire Inc.
Nov 29, 2024 6:00 PM GMT
SAN FRANCISCO and WALTHAM, Mass., Nov. 29, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inf